Is an exam required before a patient can be treated in Michigan?
Intake · part of The Practice Perimeter
Short answer
The cited rules do not settle this — Part 161's section index shows no pre-treatment exam rule for toxin or filler, while Schedule 2–5 prescribing does require a bona fide prescriber-patient relationship plus follow-up care or referral.
⚠️ Michigan splits by drug schedule, not by procedure. part 161 of the Public Health Code was surveyed via its section index and imposes no pre-treatment examination requirement for cosmetic injectables. But § 333.7303a(2) bars prescribing any SCHEDULE 2 TO 5 controlled substance outside a bona fide prescriber-patient relationship, with a follow-up care duty attached. Testosterone is Schedule III, so a hormone-therapy practice is inside that rule.
Drawn from 3 verified rules in this section · regulatory monitoring, not legal advice
- Mich. Comp. Laws pt. 161 — section index (surveyed in full) · Sep 2, 2026
- Mich. Comp. Laws § 333.7303a(2) · Sep 2, 2026
- Mich. Comp. Laws § 333.16284 · Sep 2, 2026
Related Michigan rules
⚠️ no examination rule for cosmetic injectables. Part 161 of the Public Health Code was surveyed via the section index and imposes no pre-treatment or “good faith” examination requirement for botulinum toxin or fillers. ⚠️ read that strictly — it is about NON-CONTROLLED cosmetic drugs. Controlled substances are governed separately by § 333.7303a(2) below, and testosterone is Schedule III.
Mich. Comp. Laws pt. 161 — section index (surveyed in full) · verified Sep 2, 2026 · read at Internet Archive snapshot — evidence of a page, not the current rule
⚠️ and the controlled-substance rule is a relationship test with a follow-up duty. “a licensed prescriber shall not prescribe a controlled substance listed in schedules 2 TO 5 unless the prescriber is in a bona fide prescriber-patient relationship with the patient for whom the controlled substance is being prescribed”, and the prescriber “shall provide follow-up care to the patient to monitor the efficacy” of the treatment — or refer the patient to their primary care provider, or to another geographically accessible prescriber, if unable to.
Mich. Comp. Laws § 333.7303a(2) · verified Sep 2, 2026 · read at Internet Archive snapshot — evidence of a page, not the current rule
How other states answer this
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Related Michigan questions
- Can the pre-treatment exam be done by telehealth in Michigan?
- Must someone be on site while a patient is treated in Michigan?
- Can a med spa in Michigan offer compounded semaglutide or tirzepatide?
Get Michigan changes as they publish
We scan the Michigan legislature and licensing boards daily, plus the FDA and the Federal Register. Free weekly Brief — what changed, in plain language, with the source.
Free · unsubscribe in one click · we never sell your address
← All Michigan rules and changes · MedSpaRadar is regulatory monitoring and reference: it summarizes public laws, regulations and agency actions and links each to its source. It is not legal, medical, or compliance advice, and using it creates no attorney-client relationship. A summary can lag its source or leave out detail, and monitoring itself can be interrupted — so an absence of alerts means nothing reached you, not that nothing happened. Read the cited source, check its effective date, and confirm any change to your operations or clinical practice with qualified health-law counsel and your medical director. Legislative data via LegiScan (CC BY 4.0).